Pierre Fabre Laboratories and RedRidge Bio Announce Drug Discovery and Co-development Partnership
“Pierre Fabre Laboratories are excited to enter into this agreement with RedRidge, which confirms our commitment to collaborate with innovative biotechnology companies. This partnership will allow us to capitalize on RedRidge’s cutting-edge expertise in biparatopic antibody drug discovery to deliver high quality clinical candidates on multiple targets addressing oncology, dermatology and rare diseases. It represents a significant milestone in the implementation of our strategy to enrich further our R&D pipeline”, said Dr Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre.
Share:
More News
“FAP is a high-potential target with expression in 75% of solid tumors,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome. “We believe an optimized radioligand therapy is well-suited to FAP’s intriguing biology. IM-3050 is designed to deliver radioactive lutetium-177 directly to FAP-expressing cells, and we look forward to evaluating
“We are excited to have restarted our Phase 2 study in presurgical triple-negative breast cancer. Triple-negative is a deadly and aggressive form of breast cancer, and patients having local disease currently undergo a harsh six-month regimen whereby a small percentage can die from the SOC before their surgery,” said Intensity
“TRAVERSE represents a potential breakthrough for both Allogene and the broader CAR T field,” said Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene. “CAR T has transformed hematologic malignancies while solid tumors have remained one of the field’s most difficult challenges. When we designed ALLO-316 with the
“We continue to be very encouraged by the longer-term data from our Phase 2 J201 study, and today’s announcement marks a pivotal step forward in our mission to bring safusidenib as a comprehensive treatment option for patients with all types of IDH1-mutant glioma,” said David Hung, M.D., Founder, President, and